Livongo and Dexcom Partner to Integrate Dexcom’s G6 Continuous Glucose Monitoring System into Livongo’s Applied Health Signals Platform

Dexcom CGM to become a core part of Livongo’s solution for delivering personalized health insights and improved clinical outcomes to people with Diabetes

Livongo (Nasdaq: LVGO), a leading Applied Health Signals company empowering people with chronic conditions to live better and healthier lives, has partnered with Dexcom, Inc. (NASDAQ: DXCM), a leader in continuous glucose monitoring (CGM), to offer Livongo Members the ability to synch data from their Dexcom G6 Continuous Glucose Monitoring System with the Livongo platform, providing access to key insights and Health Nudges™ from Livongo’s Applied Health Signals platform based on their CGM data.

The Dexcom G6 system accurately measures glucose levels just beneath the surface of the skin and sends data wirelessly every five minutes. The G6 includes a slim, water-resistant sensor that is discreet, easy to insert, and is FDA-cleared to make diabetes treatment decisions without confirmatory fingersticks or calibration*. The system features customizable alarms and alerts to warn users of dangerous glucose levels, even while they are asleep.

“Combining Dexcom’s leading Continuous Glucose Monitoring technology with Livongo’s Applied Health Signals platform will give our Members the next level of vital data insights they need to effectively manage their diabetes and all aspects of their health,” said Livongo Chief Executive Officer Zane Burke. “As Livongo consistently delivers an industry leading Member experience, clinical outcomes, and validated costs savings, we continue to gain momentum in partnering with other innovative organizations across the healthcare ecosystem that enhance our AI+AI engine and provide an even better experience for our Members. Our new partnership with Dexcom is a significant step in our journey to make it easier for our Members to stay healthy.”

Through the partnership, Livongo can now aggregate data from the Dexcom G6, cross-reference with proprietary blood pressure and weight data from its connected devices, and then use advanced data science to interpret that data and offer Members personalized health insights, or Health Nudges, based on their comprehensive health profile. Joint Livongo and Dexcom Members will also have access to 24/7 support from Livongo’s certified health coaches.

“Together, Dexcom and Livongo provide the opportunity for people with diabetes to easily access the leading technology and insights they need to stay healthy,” said Kevin Sayer, Chairman, President and Chief Executive Officer of Dexcom. “Through a careful combination of clinical expertise, data science, and human coaching, the combined solution offers our users an even greater ability to understand themselves, their conditions, and what they need to get and stay healthy.”

As of September 30, 2019, Livongo currently has more than 770 clients, including more than 20 percent of Fortune 500 companies, four of the top seven health plans, and two of the nation’s largest pharmacy benefit managers as partners. A 2019 study in collaboration with Eli Lilly and Company demonstrated that Livongo for Diabetes Members were more empowered and less distressed in diabetes self-management, when compared to non-Members. A separate 2019 Journal of Medical Economics study found that the Livongo for Diabetes program delivered an $88 per member monthly reduction in medical spending for Livongo Members and that employers experienced a positive return on investment in one year1.


* Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings.
1 Christopher M. Whaley, Jennifer B. Bollyky, Wei Lu, Stefanie Painter, Jennifer Schneider, Zhenxiang Zhao, Xuanyao He, Jennal Johnson & Eric S. Meadows (2019) Reduced medical spending associated with increased use of a remote diabetes management program and lower mean blood glucose values, Journal of Medical Economics, 22:9, 869-877, DOI: 10.1080/13696998.2019.1609483